Conor O’Brien

Residex BV is a private equity and venture capital fund manager based in Apeldoorn, Netherlands. Residex traces their history to 1987 when the firm was set up as Participatiemaatschappij BV in The Hague. The current firm was formally established in 1991. Residex is a subsidiary of Achmea Holding NV which provides insurance and financial services. The ultimate parent firm is Eureko BV, which offers insurance services as well as asset management and banking services. Since 1996, Residex focuses on investments in the healthcare sector and specializes in expansion capital, MBOs, MBIs and re-structuring transactions. They manage a number of venture funds with a healthcare/life sciences focus as well as those in biotechnology and the pharmaceutical industries.

Astellas Pharma SAS wholesales pharmaceutical products. The company was founded in 2005 and is headquartered in Levallois-Perret, France.

Nutrileads BV develops food ingredi?nts with a specific nutritional value. It identifies promising lead ingredients, develops sustainable and commercially viable production processes and initiates scientific and clinical programs to test the health effects. The company was founded in 2012 by Erik Dam and Ruud Albers and is headquartered in Wageningen, the Netherlands.

FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016.

Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023.

EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020.

Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019.

Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands.

NightBalance BV develops and markets sensor-devices for the treatment of sleep apnea. It offers sleep position trainer, a small and light aid which can be worn around the chest with an ergonomic band. The firm's a sleep position sensor which gradually and comfortably trains patients using vibrations to not sleep on their back. The company was founded by Eline van Beest and Thijs van Oorschot in 2009 and is headquartered in The Hague, the Netherlands.

Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium.

DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

Health Innovations BV is an independent private equity firm founded in 2011. The firm is headquartered in Utrecht, the Netherlands.

Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands.

Thuja Capital Management BV is a Venture Capital firm, a subsidiary of Thuja Capital Holding BV founded in 2006 by Harrold van Barlingen. Thuja Capital Management BV is headquartered in Utrecht.

DSM Agro BV produces and sells nitrogen fertilizers and industrial products. It offers fertilizers like Nutramon 27 N + 4 MgO, Ammonium nitrate 33.5 N, Agnesamon 22 N + 7 MgO and Urean. The company is headquartered in Sittard, the Netherlands.

BioMedbooster BV provides valorization services. It supports businesses in translating their inventions or ideas into products ready for marketing. The company builds bridges between scientific research and industry, especially in life sciences and biomedical technologies. The firm offers evaluation of commercial potential of the invention, market analysis, managing the patenting process, business plan development, financial support for patent application in selected cases, business development financing, finding seed capital, monitoring contracts and payments, strong connections in scientific, industrial and financial communities, finding licensees and monitoring patent infringement. BioMedbooster was founded in 2005 and is headquartered in Maastricht, the Netherlands.

Brightlands Venture Partners is an independent regional venture capital firm headquartered in Brightlands, Netherlands. The firm was founded in 2004.

Brabantse Ontwikkelings Maatschappij Holding BV (BOM) is an industrial and economic development agency headquarterd in Tilburg in the southern Netherlands. Established in 1983, BOM is funded and financed by the Dutch State and the Province of Noord-Brabant. The firm offers a range of services designed to create, develop, maintain and improve the industrial structure of the region through four core activities: venture capital, foreign investment, new business and industrial parks. In particular BOM manages the Technostartersfonds, also known as the TechnoStars funds, which are regional venture capital investment vehicles based in Eindhoven. The investors are primarily institutions and high-net worth private individuals.

NV Limburgs Instituut voor Ontwikkeling en Financiering (LIOF) is a private equity & venture capital firm, a subsidiary of Government of the Netherlands founded in 1935. NV Limburgs Instituut voor Ontwikkeling en Financiering is headquartered in Maastricht, the Neterlands.

Livassured BV develops monitoring devices for epilepsy patients that identifies nocturnal seizures. The company was founded by Mark Bloemendaal and Asmund Tielens and is headquartered in Vught, the Netherlands.

CimCure BV is a Dutch new generation company founded in 2015 as a spin-off of the VU University Medical Center. CimCure is based in Amsterdam, Netherlands. The company focuses on the design and development of a novel class of active cancer vaccines that target the tumor blood vessels common to most solid tumors. CimCure has discovered and patented multiple highly specific targets and a novel conjugate vaccine technology that can induce polyclonal antibody responses to targets specific to the tumor vasculature. The company aims to combine the proven efficacy of tumor angiogenesis inhibition with the advantages that a vaccine may provide. The company was founded in 2015 by Arjan W. Griffioen, and Diederik Engbersen has been the CEO of the company since 2020.